PRNANO is an open access, international society journal, published online only. Articles appear continuously on a rolling basis, then organized into quarterly issues (January, April, July, and October). All content is licensed under the Creative Commons CC BY-NC-SA 4.0 license. The mission of our journal is to promote all practical, rational, and progressive aspects of nanomedicine including theory and practice. Authors are invited to send submissions in basic science, translational, preclinical, and clinical research. PRNANO accepts original manuscripts, as well as replication studies and discussions of negative results as long as they are clearly marked as such and move the field forward. Aim and scope of the journal is to provide a good quality and supportive publishing forum with quick turnaround time for nanomedicine researchers and provide reliable and cutting-edge information to their societies and to libraries without additional cost.
NOTE: We are signatories of the San Francisco Declaration on Research Assessment and we advise against the use of journal-based metrics, such as Journal Impact Factors, as a surrogate measure of the quality of individual research articles, to assess an individual scientist’s contributions, or in hiring, promotion, or funding decisions. We support article-based metrics. There are no APC-s in 2019. In the future, our journal fees (if any) will always reflect realistic costs and will be clearly displayed on our home page. We follow the publication policies of WHO as well as the principles and guidelines of COPE.
European countries have invested heavily in Nanomedicine over the last decade, however, the output has been much reduced by a lack of knowledge of how to innovate in a heavily regulated setting. This development failing is not unique to nanomedicine but is there to differing extents across most open innovation healthcare projects. The transition from research to development requires informed debate and high-quality data and is a very challenging milestone. Researchers often say they are developing a new drug, when they are in fact doing research – funders also use the terms (R or D) interchangeably - an unfortunate consequence of their academic training. A simple test is if you don’t know actually what you are developing - you are in research.
This group does not have any discussions yet.